Immutep Ltd (ASX: IMM) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Immutep Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $316.18 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 854.12 million
Earnings per share -0.031
Dividend per share N/A
Year To Date Return -29.59%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Immutep Ltd (ASX: IMM)
Latest News

Two happy scientists analysing test results.
Healthcare Shares

10-baggers? Expert names 2 super-cheap biotech ASX shares

Biotech and health tech stocks have suffered greatly in recent months. But one fund manager is sticking by 2 particular…

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Do ASX biotech shares offer ‘good buying’ after the sell-off? Experts weigh in

After some strong support in early 2021, biotechnology stocks took a beating over the past 6 months.

Read more »

four people celebrate with champagne in front of gold 2022 balloons
Best Shares

Top ASX shares to buy in January 2022

Made some new-year's investing resolutions? Here are some expert stock picks to consider inviting to the party.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

3 ASX biotech shares rated as buys in 2022

We hear the expert opinion of analysts covering the space.

Read more »

Man in whit coat after explosion.
Healthcare Shares

2 ASX healthcare shares set to explode 70% in 2022: expert

Biotech and health stocks can fluctuate wildly, but when things go right they can be very rewarding for investors. Here's…

Read more »

Photo of a group of Imagion scientists cheering while working in a lab. as the Imagion share price skyrockets today on positive study results
Healthcare Shares

Here’s why the Immutep (ASX:IMM) share price is up today

Immutep has signed a new agreement on a key antibody product.

Read more »

young female doctor with digital tablet looking confused.
Healthcare Shares

Immutep (ASX:IMM) share price slips amid trial safety update

Initial study results look promising but investors don't appear too excited...

Read more »

share price dropping
Share Market News

Why Afterpay, Immutep, Pushpay, and Vulcan shares are falling

These ASX shares are in the red today...

Read more »

IMM ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Immutep Ltd

Immutep Ltd is a biotechnology company headquartered in Australia that focuses on personalised bio-therapeutic products for cancer.

IMM Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
13 May 2022 $0.35 $0.00 0.00% 1,018,382 $0.34 $0.35 $0.33
12 May 2022 $0.35 $-0.01 -2.82% 1,419,981 $0.34 $0.35 $0.33
11 May 2022 $0.36 $0.02 5.88% 1,170,750 $0.35 $0.36 $0.34
10 May 2022 $0.34 $0.00 0.00% 1,599,757 $0.33 $0.35 $0.32
09 May 2022 $0.34 $-0.01 -2.86% 2,047,136 $0.35 $0.35 $0.34
06 May 2022 $0.35 $-0.01 -2.82% 1,017,985 $0.34 $0.35 $0.33
05 May 2022 $0.36 $0.03 9.09% 1,231,625 $0.35 $0.37 $0.35
04 May 2022 $0.33 $0.00 0.00% 1,120,142 $0.33 $0.34 $0.32
03 May 2022 $0.33 $0.00 0.00% 1,183,322 $0.33 $0.34 $0.32
02 May 2022 $0.33 $-0.01 -2.94% 889,697 $0.33 $0.34 $0.33
29 Apr 2022 $0.34 $0.02 6.15% 1,286,549 $0.34 $0.35 $0.33
28 Apr 2022 $0.33 $0.01 3.17% 1,419,107 $0.32 $0.33 $0.31
27 Apr 2022 $0.32 $-0.01 -3.13% 1,283,884 $0.32 $0.32 $0.31
26 Apr 2022 $0.32 $-0.01 -3.08% 1,146,957 $0.33 $0.33 $0.32
22 Apr 2022 $0.33 $-0.01 -2.99% 1,290,273 $0.33 $0.34 $0.32
21 Apr 2022 $0.34 $-0.02 -5.71% 1,220,854 $0.35 $0.35 $0.33
20 Apr 2022 $0.35 $0.01 2.90% 751,944 $0.34 $0.36 $0.34

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
01 Dec 2021 Russell Howard Exercise 250 $118,750
Conversion of securities.
01 Dec 2021 Russell Howard Issued 339 $161,319
Issue of securities. 339,621 - Director Performance Rights
01 Dec 2021 Russell Howard Buy 250 $118,750
Conversion of securities.
01 Dec 2021 Marc Voigt Issued 3 $1,710,000
Issue of securities. 6,000,000 - Performance Rights
04 Oct 2021 Grant Chamberlain Buy 450 $240,750
Conversion of securities.
04 Oct 2021 Pete Meyers Exercise 500 $267,500
Conversion of securities. 1,000,000 - Performance Rights
04 Oct 2021 Grant Chamberlain Exercise 450 $240,750
Conversion of securities. 900,000 - Performance Rights
04 Oct 2021 Pete Meyers Buy 500 $267,500
Conversion of securities.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Ms Lucinda (Lucy) Turnbull Non-Executive Director Feb 2022
Ms Turnbull has previously served as Chairman from 06 October 2010 to 17 November 2017 of Immutep Limited. Ms Turnbull is an Australian businesswoman, philanthropist and former local government politician. With a background in commercial law and investment banking, she was the first female Lord Mayor of the City of Sydney from 2003 to 2004 and has served on the boards of the NSW Cancer Institute, the Sydney Children's Hospital Foundation, the Sydney Cancer Centre and the Sydney Festival. From 2015 to 2020 she served as the inaugural Chief Commissioner of the Greater Sydney Commission, a NSW state government body focused on delivering strategic planning for the whole of metropolitan Sydney.
Dr Russell J Howard Non-Executive ChairmanNon-Executive Director May 2013
Dr Howard is an Australian scientist, executive manager, and entrepreneur. He was a pioneer in molecular parasitology and commercialisation of DNA Shuffling. He is an inventor of 9 patents and has over 140 scientific publications. After his PhD in biochemistry from the University of Melbourne, he held positions at several research laboratories, including the National Institutes of Health in the USA where he gained tenure. In industry, Dr Howard worked at Schering Plough's DNAX Research Institute in Palo Alto, CA; was the President and Scientific Director of Affymax, Inc. and co-founder and CEO of Maxygen, Inc. After its spin out from GlaxoWellcome, as Maxygen's CEO, Dr. Howard led its IPO on NASDAQ and a secondary offering, raising US$ 260 million. Maxygen developed and partnered dozens of technology applications and products over 12 years of his tenure as CEO. After leaving Maxygen in 2008, he started the Cleantech company NovoNutrients Inc. (formerly Oakbio, Inc.) and remains involved in several innovative companies in the USA and Australia. He is currently Executive Chairman of NeuClone Pty Ltd.
Mr Pete A Meyers Non-Executive Deputy ChairmanNon-Executive Director Feb 2014
Mr Meyers is the Chief Financial Officer of Slayback Pharma LLC. Prior to joining Slayback, Mr Meyers served in Chief Financial Officer roles at Eagle Pharmaceuticals, Inc., Motif BioSciences Inc. and TetraLogic Pharmaceuticals Corporation. Prior to his role at TetraLogic, Mr Meyers spent 18 years in health care investment banking, holding positions of increasing responsibility at Dillon, Read &Co., Credit Suisse First Boston LLC and, most recently, as CoHead of Global Health Care Investment Banking at Deutsche Bank Securities Inc. Mr Meyers is the Chairman and President of The Thomas M. Brennan Memorial Foundation, Inc., and serves on the Board of Directors of East End Hospice, Inc.
Mr Marc Voigt Chief Financial OfficerChief Executive OfficerExecutive Director May 2012
Mr Voigt has more than 21 years of experience in the financial and biotech industry, having joined the Immutep team in 2011 as the General Manager, European Operations based in Berlin, Germany. In May 2012, he became Immutep 's Chief Business Officer and in November 2012 its Chief Financial Officer, as well as continuing to focus on its European operations. Having started his career at the Allianz Group working in pension insurances and funds, he moved to net.IPO AG, a publicly listed boutique investment bank in Frankfurt where he was focused on IPOs and venture capital investments. He then worked for a number of years as an investment manager for a midsize venture capital fund based in Berlin, specialising in healthcare. He also gained considerable operational experience while serving in different management roles with Revotar Biopharmaceuticals, Caprotec Bioanalytics and Medical Enzymes AG respectfully, where he handled several successful licensing transactions and financing rounds. Since 2001, he has been a judge and coach in BPW, Germany's largest regional start-up initiative.
Ms Deanne Miller Chief Operating OfficerCompany SecretaryGeneral Counsel
-
Ms Indira Naidu Joint Company Secretary Jan 2021
-
Deanne Miller Chief Operating OfficerCompany SecretaryGeneral Counsel
-
Dr Frederic Triebel Chief Scientific Officer & Chief Medical Officer
-
Indira Naidu Joint Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 324,272,007 38.11%
National Nominees Limited 60,483,220 7.11%
Citicorp Nominees Pty Limited 43,042,850 5.06%
J P Morgan Nominees Australia Pty Limited 31,044,298 3.65%
Cs Third Nominees Pty Limited <HSBC Cust Nom Au Ltd 13 A/C> 20,082,579 2.36%
BNP Paribas Noms Pty Ltd <DRP> 13,932,786 1.64%
HSBC Custody Nominees (Australia) Limited A/C 2 9,678,956 1.14%
Marc Voigt 8,791,695 1.03%
UBS Nominees Pty Ltd 7,199,156 0.85%
Frederic Triebel 6,853,764 0.81%
BNP Paribas Nominees Pty Ltd Acf Clearstream 6,235,332 0.73%
Sandhurst Trustees Ltd <Endeavor Asset Mgmt Mda A/C> 5,499,923 0.65%
Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 4,501,767 0.53%
Brispot Nominees Pty Ltd <House Head Nominee A/C> 4,456,012 0.52%
Macenrock Pty Ltd <Macenrock S/F A/C> 3,622,897 0.43%
Ms Lucy Turnbull 2,981,626 0.35%
Deanne Miller 2,863,892 0.34%
M & Hc Pty Ltd <Caudle Investment A/C> 2,314,372 0.27%
Mr Thomas Tscherepko 2,300,000 0.27%
Mr David Stewart Field 2,270,000 0.27%

Profile

since

Note